We’ve all heard the phrase “secrets don’t make friends.” Well, they don’t make drug treatments either.  One of Forbes magazine’s blogs, The Science Business, is publishing a series of articles on how secrecy is hurting drug research. Matthew Herper, a senior editor at Forbes, authored a piece published yesterday, June 1, on the topic and it has struck a chord here at the Myelin Repair Foundation.  He discusses the idea that it may be “a companies’ tendency to keep their research under wraps” that is holding them back, which is one of the reasons we use a collaborative model in our research method.

Herper also takes a moment to pinpoint some of the other locations across the country,  such as the University of California, San Francisco and the headquarters of the huge drug developer, GlaxoSmithKline, that have started to share information with each other in hopes of minimizing drug development costs and maximize the number of therapies and/or cures they can find. He says “Traditionally, drug companies don’t share data with each other as studies progress. Increasingly, it seems that might be a mistake.”

If you want to read more, visit:  The Science Business Blog,  Forbes Magazine

There will be articles discussing the secrecy of drug research all week. Also, check out how the Myelin Repair Foundation is using the idea of research collaboration in their ARC model at MyelinRepair.org’

Crossposted at Myelin Repair Foundation Blog

You can leave a response, or trackback from your own site.